4%, NPV 76.7%). Conclusion: Pegylated interferonα-2a induces high HBsAg loss rate in NA-experienced CHB

patients with or without virological response, however, patients with virological response and http://www.selleckchem.com/products/PF-2341066.html low qHBsAg level (<1500IU/ml) achieves higher HBsAg loss. Disclosures: The following people have nothing to disclose: Yao Xie, Ming-hui Li, Yao Lu, Guo-hua Qiu, Lu Zhang, Li-wei Zhuang, Jun Cheng Background/Aims: Tenofovir DF (TDF) represents a very efficient and safe therapy option in patients with Chronic Hepatitis B, as shown in pivotal trials over 6 years. A correlation between HBV-DNA levels and long term clinical outcomes has been reported. However, the impact of therapeutic adherence on the viral load (VL) is still poorly documented in field practice. The aim of this study is to assess behavioral

determinants of biological outcome within a cohort of selleck chemicals HBV-patients treated with TDF (VIREAL Study) in real life from France. Methods: 441 CHB patients (mean age 45.3 (SD 14.3), 70.9% males, 59.1% treatment-experienced) were invited to fill in a short self-reported adherence questionnaire at 3, 6 and 12-month. Their practitioners were also invited on the same visits to answer a short questionnaire describing patients’ knowledge about their disease, motivation, reluctance to be treated, mood, and therapeutic partnership with the practitioner. The questionnaire used three ratings to

report treatment adherence: good adherence, minor problems related to adherence and poor adherence. VL was measured at baseline, 3, 6 and 12 month. Results: HBV-DNA was lower than 69IU/mL at week 48 in 91 % of patients. Overall, good adherence was observed in 56%, minor adherence selleck screening library problems in 39% and poor adherence in 5%. Similar to registration trials for TDF, VL significantly decreased from baseline to 12 months, with a final VL positively correlated with baseline VL. After adjusting for baseline VL, higher final VL was found in patients who reported having skipped their last medication at the 3-month visit (p=0.001) or at the 12-month visit (p=0.017), patients who reported having been out of drugs at the 12-month visit (p=0.001), patients considered by their practitioner as insufficiently informed about their disease at the 3-month (p=0.02) or 12-month visits (p=0.008) or reluctant to have treatment at the 12-month visit (p=0.003). Conclusions: A simple questionnaire to CHB patients and/or to their practitioners can provide useful information about risk factors for lower efficacy of antiviral treatment in CHB. These indicators could help practitioners to better motivate and manage these patients and prevent disappointing biological results, with their at risk long term consequences. Disclosures: Jean-Pierre H.